iDRx

Blueprint Medicines

This biopharmaceutical company develops and commercialises kinase inhibitors for patients with systemic mastocytosis, gastrointestinal stromal tumours and other genomic-driven cancers.

Enedra Therapeutics Ltd

This company develops precision medicines and biomarkers to treat advanced, genetically heterogeneous cancers for patients with drug-resistant tumours.

Fore Biotherapeutics

This precision oncology company develops targeted therapies for patients with unaddressed cancer mutations, including a specific BRAF inhibitor for advanced solid tumours.

Dracen Pharmaceuticals

This biotech company develops glutamine antagonist drugs to treat lung cancer and solid tumours for patients with specific genetic mutations.

Nuvectis Pharma

This biopharmaceutical company develops precision medicines and targeted small molecule therapeutics for patients with advanced cancers and other serious conditions.

Fore Bio

This biotechnology company develops precision oncology therapies and small-molecule inhibitors for patients with unaddressed tumour mutations and hard-to-treat cancers.

BiPER Therapeutics

This company develops small molecule drugs targeting the BiP protein to treat gastrointestinal cancers and other pathological conditions in humans.

tolremo

This company develops small molecule drugs to prevent non-genetic resistance in cancer patients receiving targeted therapies.